Close

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer enabled therapeutics

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, announce a research collaboration to identify new Optimer-enabled therapeutics.

The collaboration will aim to identify Optimers for use as Optimer-drug conjugates for targeted delivery of diverse payloads to new cellular targets. Achieving targeted delivery of drugs to specific tissues and organs can increase the therapeutic dose at site of action to increase therapeutic efficacy, and reduce off-target effects to improve patient tolerability. This remains a major translational challenge for many new precision medicines.

As part of the agreement, Aptamer Group will develop Optimers to specific disease biomarkers and supply them to WuXi AppTec Research Service Division for further evaluation as potential delivery vehicles.

Dr Arron Tolley, chief executive officer of Aptamer Group, commented: “Aptamer Group is pleased to be developing novel Optimers for use as delivery vehicles in partnership with WuXi AppTec Research Service Division. This work further validates our Optimer platform as a flexible solution that can be integrated into therapeutic pipelines to potentially accelerate development and deliver important, life-changing therapeutics for patients with hard to treat diseases.”

Aptamer Group is a leading provider of Optimer reagents for use in research, diagnostics and therapeutics.

The WuXi AppTec Research Service Division (RSD) supports clients in the discovery and development of future therapeutics.

Latest stories

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back